Quotient Sciences advances AI-designed drug product into Phase I clinical study

Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.

Enveric reports key safety milestone for EB-003 reinforcing clinical development path

The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors

Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks

Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

Dr. Abhigyan Upadhyay to lead Platinum Industries foray into life sciences

Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy